5-amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes

Diabetes. 2003 May;52(5):1066-72. doi: 10.2337/diabetes.52.5.1066.

Abstract

AMP-activated protein kinase (AMPK) activation by AICAR (5-amino-imidazole carboxamide riboside) is correlated with increased glucose transport in rodent skeletal muscle via an insulin-independent pathway. We determined in vitro effects of insulin and/or AICAR exposure on glucose transport and cell-surface GLUT4 content in skeletal muscle from nondiabetic men and men with type 2 diabetes. AICAR increased glucose transport in a dose-dependent manner in healthy subjects. Insulin and AICAR increased glucose transport and cell-surface GLUT4 content to a similar extent in control subjects. In contrast, insulin- and AICAR-stimulated responses on glucose transport and cell-surface GLUT4 content were impaired in subjects with type 2 diabetes. Importantly, exposure of type 2 diabetic skeletal muscle to a combination of insulin and AICAR increased glucose transport and cell-surface GLUT4 content to levels achieved in control subjects. AICAR increased AMPK and acetyl-CoA carboxylase phosphorylation to a similar extent in skeletal muscle from subjects with type 2 diabetes and nondiabetic subjects. Our studies highlight the potential importance of AMPK-dependent pathways in the regulation of GLUT4 and glucose transport activity in insulin-resistant skeletal muscle. Activation of AMPK is an attractive strategy to enhance glucose transport through increased cell surface GLUT4 content in insulin-resistant skeletal muscle.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoimidazole Carboxamide / analogs & derivatives*
  • Aminoimidazole Carboxamide / therapeutic use*
  • Biological Transport / drug effects
  • Body Mass Index
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism*
  • Glucose / metabolism*
  • Glucose Transporter Type 4
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • In Vitro Techniques
  • Insulin / therapeutic use
  • Middle Aged
  • Monosaccharide Transport Proteins / metabolism*
  • Muscle Proteins*
  • Muscle, Skeletal / metabolism*
  • Oxygen Consumption / drug effects
  • Reference Values
  • Ribonucleotides / therapeutic use*

Substances

  • Glucose Transporter Type 4
  • Hypoglycemic Agents
  • Insulin
  • Monosaccharide Transport Proteins
  • Muscle Proteins
  • Ribonucleotides
  • SLC2A4 protein, human
  • Aminoimidazole Carboxamide
  • AICA ribonucleotide
  • Glucose